21 mayo 2015
First study of the genomic composition of prostate cancer shows many patients have gene mutations that can be targeted with existing or potential drugs. The finding is based on an analysis of tumor samples from 150 men with metastatic prostate cancer that no longer responded to standard hormone-blocking therapy.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/HovTPJWeE5Y/150521133734.htm
